Pexidartinib Hydrochloride Patent Expiration
Pexidartinib Hydrochloride is Used for treating adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations that are not improved with surgery. It was first introduced by Daiichi Sankyo Inc
Pexidartinib Hydrochloride Patents
Given below is the list of patents protecting Pexidartinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Turalio | US10435404 | Formulations of a compound modulating kinases | Jul 24, 2038 | Daiichi Sankyo Inc |
| Turalio | US10941142 | Formulations of a compound modulating kinases | Jul 24, 2038 | Daiichi Sankyo Inc |
| Turalio | US10961240 | Formulations of a compound modulating kinases | Jul 24, 2038 | Daiichi Sankyo Inc |
| Turalio | US10189833 | Solid forms of a compound modulating kinases | May 05, 2036 | Daiichi Sankyo Inc |
| Turalio | US10730876 | Synthesis of a compound that modulates kinases | May 05, 2036 | Daiichi Sankyo Inc |
| Turalio | US9802932 | Solid forms of a compound modulating kinases | May 05, 2036 | Daiichi Sankyo Inc |
| Turalio | US9358235 | Kinase modulation, and indications therefor | Jun 08, 2033 | Daiichi Sankyo Inc |
| Turalio | US7893075 | Compounds modulating c-fms and/or c-kit activity and uses therefor | May 04, 2033 | Daiichi Sankyo Inc |
| Turalio | US8461169 | Compounds modulating c-fms and/or c-kit activity | Apr 19, 2028 | Daiichi Sankyo Inc |
| Turalio | US8404700 | Compounds modulating c-fms and/or c-kit activity and uses therefor | Nov 21, 2027 | Daiichi Sankyo Inc |
| Turalio | US8722702 | Compounds modulating c-fms and/or c-kit activity and uses therefor | Nov 21, 2027 | Daiichi Sankyo Inc |
| Turalio | US9169250 | Compounds modulating c-fms and/or c-kit activity and uses therefor | Nov 21, 2027 | Daiichi Sankyo Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Pexidartinib Hydrochloride's patents.
Latest Legal Activities on Pexidartinib Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Pexidartinib Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Feb, 2024 | US10730876 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2023 | US9169250 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Apr, 2023 | US10435404 |
| Patent Term Extension Certificate Critical | 06 Oct, 2022 | US7893075 |
| Withdrawal of Application for PTE Critical | 30 Aug, 2022 | US8461169 |
| Withdrawal of Application for PTE Critical | 30 Aug, 2022 | US9169250 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Aug, 2022 | US7893075 |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Aug, 2022 | US10435404 |
| Filing Receipt - Corrected | 09 Aug, 2022 | US10189833 |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Aug, 2022 | US10730876 |
Pexidartinib Hydrochloride's Family Patents
